Erik Jakobsen

17.8k total citations · 1 hit paper
151 papers, 4.3k citations indexed

About

Erik Jakobsen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Erik Jakobsen has authored 151 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 85 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Erik Jakobsen's work include Lung Cancer Treatments and Mutations (45 papers), Lung Cancer Diagnosis and Treatment (41 papers) and HER2/EGFR in Cancer Research (33 papers). Erik Jakobsen is often cited by papers focused on Lung Cancer Treatments and Mutations (45 papers), Lung Cancer Diagnosis and Treatment (41 papers) and HER2/EGFR in Cancer Research (33 papers). Erik Jakobsen collaborates with scholars based in Denmark, United Kingdom and United States. Erik Jakobsen's co-authors include Anders Green, Lars Stenbygaard, Torben Riis Rasmussen, Henrik Møller, Maria Iachina, Maj‐Britt Jensen, Dorte Nielsen, Anders Jakobsen, Søren Cold and Marianne Ewertz and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Erik Jakobsen

143 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

2007 693 citations Erik Jakobsen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Erik Jakobsen

Since Specialization

Citations

This map shows the geographic impact of Erik Jakobsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Jakobsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Jakobsen more than expected).

Fields of papers citing papers by Erik Jakobsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Jakobsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Jakobsen. The network helps show where Erik Jakobsen may publish in the future.

Co-authorship network of co-authors of Erik Jakobsen

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Jakobsen. A scholar is included among the top collaborators of Erik Jakobsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Jakobsen. Erik Jakobsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost 2024 ·Radiotherapy and Oncology ·Mette S. Thomsen, Jan Alsner, Christina Maria Lutz, Martin Berg, Ingelise Jensen, Ebbe Laugaard Lorenzen, Hanne Melgaard Nielsen, Erik Jakobsen, Lars Stenbygaard, Mette Holck Nielsen, Maj‐Britt Jensen, Jens Overgaard, Birgitte Vrou Offersen	2
2	Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung Cancer in Routine Clinical Practice: A Nationwide Cohort Study 2024 ·JCO Oncology Practice ·Anne Gulbech Ording, Flemming Skjøth, Laurids Østergaard Poulsen, (unknown), Erik Jakobsen, Thomas Decker Christensen, Simon Noble, Thure Filskov Overvad	7
3	Cohort Profile: The Danish SEQUEL cohort 2024 ·International Journal of Epidemiology ·(unknown), Susanne Oksbjerg Dalton, Lau Caspar Thygesen, Erik Jakobsen, Ismail Gögenür, Michael Borre, Robert Zachariae, Peer Christiansen, Søren Laurberg, Peter Christensen, Lisbet Rosenkrantz Hölmich, Peter de Nully Brown, Christoffer Johansen, Susanne K. Kjær, Lonneke V. van de Poll‐Franse, Trille Kristina Kjær	1
4	Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study 2024 ·Clinical Lung Cancer ·Anne Gulbech Ording, Thomas Decker Christensen, Flemming Skjøth, Simon Noble, (unknown), (unknown), Torben Bjerregaard Larsen, René Horsleben Petersen, Peter Meldgaard, Erik Jakobsen, Mette Søgaard	4
5	Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial 2024 ·Journal of Clinical Oncology ·Maj‐Britt Jensen, Eva Balslev, Ann Knoop, Malgorzata Tuxen, Inger Højris, Erik Jakobsen, Søren Cold, Hella Danø, Vesna Glavicic, (unknown), Bent Ejlertsen	3
6	Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA 2023 ·Scientific Reports ·(unknown), Søren Kahns, Signe Timm, Rikke Fredslund Andersen, Jonna Skov Madsen, Erik Jakobsen, (unknown), Anders Jakobsen, Troels Bechmann	12
7	Social inequality in cancer survivorship: Educational differences in health‐related quality of life among 27,857 cancer survivors in Denmark 2023 ·Cancer Medicine ·(unknown), Trille Kristina Kjær, Lau Caspar Thygesen, (unknown), Erik Jakobsen, Ismail Gögenür, Michael Borre, Peer Christiansen, Robert Zachariae, Peter Christensen, Søren Laurberg, Peter de Nully Brown, Lisbet Rosenkrantz Hölmich, Christoffer Johansen, Susanne K. Kjær, Lonneke V. van de Poll‐Franse, (unknown), Susanne Oksbjerg Dalton	12
8	Offline Stimulation Through a TAML Level 5 Multilateral Junction: Operational Success Within a Carbonate Formation Through Design Collaboration and Joint Planning 2023 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Erik Jakobsen	2
9	Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial 2022 ·Radiotherapy and Oncology ·Mette S. Thomsen, Jan Alsner, Hanne Melgaard Nielsen, Erik Jakobsen, Mette Holck Nielsen, (unknown), Anders N. Pedersen, Esben Svitzer Yates, Martin Berg, Ebbe Laugaard Lorenzen, Ingelise Jensen, Mirjana Josipović, Jens Overgaard, Birgitte Vrou Offersen	21
10	Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial 2022 ·Journal of Clinical Oncology ·Birgitte Vrou Offersen, Jan Alsner, Hanne Melgaard Nielsen, Erik Jakobsen, Mette Holck Nielsen, Lars Stenbygaard, Anders N. Pedersen, Mette S. Thomsen, Esben Svitzer Yates, Martin Berg, Ebbe Laugaard Lorenzen, Ingelise Jensen, Mirjana Josipović, Maj‐Britt Jensen, Jens Overgaard	44
11	NAVIGATE: improving survival in vulnerable patients with lung cancer through nurse navigation, symptom monitoring and exercise – study protocol for a multicentre randomised controlled trial 2022 ·BMJ Open ·(unknown), Susanne Oksbjerg Dalton, Erik Jakobsen, Randi V. Karlsen, Maria Iachina, Karen M. Freund, Amy LeClair, Anette Søgaard Nielsen, Elisabeth Wreford Andersen, Susanne Rosthøj, (unknown), Søren Thorgaard Skou, Pernille Envold Bidstrup	4
12	Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG) 2020 ·The Breast ·Tobias Berg, Maj‐Britt Jensen, Erik Jakobsen, (unknown), (unknown), Michael Andersson	13
13	The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates 2014 ·BMJ Open ·Maria Iachina, Anders Green, Erik Jakobsen	29
14	High Procedure Volume Is Strongly Associated With Improved Survival After Lung Cancer Surgery 2013 ·Journal of Clinical Oncology ·Margreet Lüchtenborg, Sharma P. Riaz, Victoria H. Coupland, Eric Lim, Erik Jakobsen, Mark Krasnik, Richard Page, Michael Lind, Michael Peake, Henrik Møller	153
15	Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer 2013 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·(unknown), (unknown), Erik Jakobsen, Jonna Skov Madsen, Ivan Brandslund	13
16	Nationwide Quality Improvement in Lung Cancer Care: The Role of the Danish Lung Cancer Group and Registry 2013 ·Journal of Thoracic Oncology ·Erik Jakobsen, Anders Green, (unknown), Torben Riis Rasmussen, Maria Iachina, Torben Palshof	97
17	Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer. 2012 ·PubMed ·(unknown), Rikke Fredslund Andersen, Karina Dahl Steffensen, Erik Jakobsen, Ivan Brandslund, Flemming Brandt Sørensen, Anders Jakobsen	10
18	Dansk Lunge Cancer Register 2012 ·Ugeskrift for Læger ·Erik Jakobsen, Anders Green, Kell Østerlind, Torben Palshof	0
19	Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting 2009 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·(unknown), Erik Jakobsen, Sven Tyge Langkjer, Susanne Bokmand, (unknown), Dorte Aalund Olsen, Jonna Skov Madsen, Ivan Brandslund	20
20	HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue 2009 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·(unknown), (unknown), Susanne Bokmand, (unknown), Erik Jakobsen, Anders Jakobsen, Ivan Brandslund	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact